Patient-reported outcomes in the single-tablet regimen (STaR) trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate in antiretroviral treatment-naive adults infected with HIV-1 through 48 weeks of treatment

References

• Al-Dakkak, I., Patel, S., McCann, E., Gadkari, A., Prajapati, G., & Maiese, E. M. (2013). The impact of specific HIV treatment-related adverse events on adherence to antiretroviral therapy: A systematic review and meta-analysis. AIDS Care, 25(4), 400–414. doi:10.1080/09540121.2012.712667
   PubMed Web of Science ®Google Scholar
• Aldir, I., Horta, A., & Serrado, M. (2014). Single-tablet regimens in HIV: Does it really make a difference? Current Medical Research and Opinion, 30(1), 89–97. doi:10.1185/03007995.2013.844685
   PubMed Web of Science ®Google Scholar
• Ammassari, A., Murri, R., Pezzotti, P., Trotta, M. P., Ravasio, L., De Longis, P., … Antinori, A. (2001). Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection. JAIDS Journal of Acquired Immune Deficiency Syndromes, 28(5), 445–449. doi: 10.1097/00042560-200112150-00006
   PubMed Web of Science ®Google Scholar
• Barfod, T. S., Gerstoft, J., Rodkjaer, L., Pedersen, C., Nielsen, H., Moller, A., … Obel, N. (2005). Patients’ answers to simple questions about treatment satisfaction and adherence and depression are associated with failure of HAART: A cross-sectional survey. AIDS Patient Care and STDs, 19(5), 317–325. doi:10.1089/apc.2005.19.317
   PubMed Web of Science ®Google Scholar
• Behrens, G., Rijnders, B., Nelson, M., Orkin, C., Cohen, C., Mills, A., … Chuck, S. K. (2014). Rilpivirine versus efavirenz with emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected patients with HIV-1 RNA ≤100,000 copies/mL: Week 96 pooled ECHO/THRIVE subanalysis. AIDS Patient Care and STDs, 28(4), 168–175. doi:10.1089/apc.2013.0310
   PubMed Web of Science ®Google Scholar
• Boyd, M. A. (2009). Improvements in antiretroviral therapy outcomes over calendar time. Current Opinion in HIV and AIDS, 4(3), 194–199. doi:10.1097/COH.0b013e328329fc8d
   PubMed Web of Science ®Google Scholar
• de Boer, I. M., Prins, J. M., Sprangers, M. A., Smit, C., & Nieuwkerk, P. T. (2011). Self-reported symptoms among HIV-infected patients on highly active antiretroviral therapy in the ATHENA cohort in The Netherlands. HIV Clinical Trials, 12(3), 161–170. doi:10.1310/hct1203-161
   PubMed Web of Science ®Google Scholar
• Brigido, L. F., Rodrigues, R., Casseb, J., Oliveira, D., Rossetti, M., Menezes, P., & Duarte, A. J. (2001). Impact of adherence to antiretroviral therapy in HIV-1-infected patients at a university public service in Brazil. AIDS Patient Care and STDs, 15(11), 587–593. doi:10.1089/108729101753287685
   PubMed Web of Science ®Google Scholar
• Cahn, P., Vibhagool, A., Schechter, M., Soto-Ramirez, L., Carosi, G., Smaill, F., … Steel, H. M. (2004). Predictors of adherence and virologic outcome in HIV-infected patients treated with abacavir- or indinavir-based triple combination HAART also containing lamivudine/zidovudine. Current Medical Research and Opinion, 20(7), 1115–1123. doi:10.1185/030079904125004051
   PubMed Web of Science ®Google Scholar
• Cohen, C. J., Molina, J. M., Cassetti, I., Chetchotisakd, P., Lazzarin, A., Orkin, C., … Boven, K. (2013). Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials. AIDS, 27(6), 939–950. doi:10.1097/QAD.0b013e32835cee6e
   PubMed Web of Science ®Google Scholar
• Cohen, C. J., Wohl, D., Arribas, J. R., Henry, K., Van Lunzen, J., Bloch, M., … Fralich, T. (2014). Week 48 results from a randomized clinical trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate vs. efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adults. AIDS, 28(7), 989–997. doi:10.1097/QAD.0000000000000169
   PubMed Web of Science ®Google Scholar
• Complera® (emtricitabine, rilpivirine, tenofovir disoproxil fumarate) tablets. (2014). (US ed.). Foster City, CA: Gilead Sciences, Inc. Retrieved from http://services.gileadhiv.com/complera/pdf/pi
   Google Scholar
• Duran, S., Spire, B., Raffi, F., Walter, V., Bouhour, D., Journot, V., … Moatti, J. P. (2001). Self-reported symptoms after initiation of a protease inhibitor in HIV-infected patients and their impact on adherence to HAART. HIV Clinical Trials, 2(1), 38–45. doi: 10.1310/R8M7-EQ0M-CNPW-39FC
   PubMedGoogle Scholar
• Edelman, E. J., Gordon, K., & Justice, A. C. (2011). Patient and provider-reported symptoms in the post-cART era. AIDS and Behavior, 15(4), 853–861. doi:10.1007/s10461-010-9706-z
   PubMed Web of Science ®Google Scholar
• Edurant® (rilpivirine) tablets. (2014). (US ed.). Titusville, NJ: Janssen Therapeutics. Retrieved from http://www.edurant.com/patients/full-product-information
   Google Scholar
• Eviplera 200 mg/25 mg/245 mg film-coated tablets. (2014). (EU ed.). Cambridge, UK Gilead Sciences International Limited. Retrieved from http://www.medicines.org.uk/emc/medicine/25518/SPC/Eviplera+200+mg+25+mg+245+mg+film+coated+tablets/
   Google Scholar
• Flandre, P., Peytavin, G., Meiffredy, V., Saidi, Y., Descamps, D., Delagnes, M., … Raffi, F. (2002). Adherence to antiretroviral therapy and outcomes in HIV-infected patients enrolled in an induction/maintenance randomized trial. Antiviral Therapy, 7(2), 113–121.
   PubMed Web of Science ®Google Scholar
• Garcia de Olalla, P., Knobel, H., Carmona, A., Guelar, A., Lopez-Colomes, J. L., & Cayla, J. A. (2002). Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients. JAIDS Journal of Acquired Immune Deficiency Syndromes, 30(1), 105–110. doi: 10.1097/00042560-200205010-00014
   PubMed Web of Science ®Google Scholar
• Gardner, E. M., Hullsiek, K. H., Telzak, E. E., Sharma, S., Peng, G., Burman, W. J., … Mannheimer, S. B. (2010). Antiretroviral medication adherence and class-specific resistance in a large prospective clinical trial. AIDS, 24(3), 395–403. doi: 10.1097/QAD.0b013e328335cd8a
   PubMed Web of Science ®Google Scholar
• Gardner, E. M., Sharma, S., Peng, G., Hullsiek, K. H., Burman, W. J., Macarthur, R. D., … Mannheimer, S. B. (2008). Differential adherence to combination antiretroviral therapy is associated with virological failure with resistance. AIDS, 22(1), 75–82. doi:10.1097/QAD.0b013e3282f366ff
   PubMed Web of Science ®Google Scholar
• Gay, C., Portillo, C. J., Kelly, R., Coggins, T., Davis, H., Aouizerat, B. E., … Lee, K. A. (2011). Self-reported medication adherence and symptom experience in adults with HIV. Journal of the Association of Nurses in AIDS Care, 22(4), 257–268. doi:10.1016/j.jana.2010.11.004
   PubMed Web of Science ®Google Scholar
• Glass, T. R., De Geest, S., Hirschel, B., Battegay, M., Furrer, H., Covassini, M., … Bucher, H. C. (2008). Self-reported non-adherence to antiretroviral therapy repeatedly assessed by two questions predicts treatment failure in virologically suppressed patients. Antiviral Therapy, 13(1), 77–85.
   PubMed Web of Science ®Google Scholar
• Gross, R., Bilker, W. B., Friedman, H. M., Coyne, J. C., & Strom, B. L. (2002). Provider inaccuracy in assessing adherence and outcomes with newly initiated antiretroviral therapy. AIDS, 16(13), 1835–1837. doi: 10.1097/00002030-200209060-00021
   PubMed Web of Science ®Google Scholar
• Guidance for Industry: Human Immunodeficiency Virus-1 Infection: Developing Antiretroviral Drugs for Treatment. (2013). Silver Spring: U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Retrieved from http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM355128.pdf
   Google Scholar
• Gupta, R., Ordonez, R. M., & Koenig, S. (2012). Global impact of antiretroviral therapy-associated diarrhea. AIDS Patient Care STDS, 26(12), 711–713. doi:10.1089/apc.2012.0299
   Google Scholar
• Hill, A., & Balkin, A. (2009). Risk factors for gastrointestinal adverse events in HIV treated and untreated patients. AIDS Review, 11(1), 30–38.
   PubMed Web of Science ®Google Scholar
• Hodder, S., Arasteh, K., De Wet, J., Gathe, J., Gold, J., Kumar, P., … Boven, K. (2012). Effect of gender and race on the week 48 findings in treatment-naive, HIV-1-infected patients enrolled in the randomized, phase III trials ECHO and THRIVE. HIV Medicine, 13(7), 406–415. doi:10.1111/j.1468-1293.2012.00991.x
   PubMed Web of Science ®Google Scholar
• Jordan, J., Cahn, P., Goebel, F., Matheron, S., Bradley, C., & Woodcock, A. (2005). Abacavir compared to protease inhibitors as part of HAART regimens for treatment of HIV infection: Patient satisfaction and implications for adherence. AIDS Patient Care and STDs, 19(1), 9–18. doi:10.1089/apc.2005.19.9
   PubMed Web of Science ®Google Scholar
• Juday, T., Gupta, S., Grimm, K., Wagner, S., & Kim, E. (2011). Factors associated with complete adherence to HIV combination antiretroviral therapy. HIV Clinical Trials, 12(2), 71–78. doi:10.1310/hct1202-71
   PubMed Web of Science ®Google Scholar
• Justice, A. C., Holmes, W., Gifford, A. L., Rabeneck, L., Zackin, R., Sinclair, G., … Wu, A. W. (2001). Development and validation of a self-completed HIV symptom index. Journal of Clinical Epidemiology, 54(Suppl. 1), S77–S90. doi: 10.1016/S0895-4356(01)00449-8
   PubMed Web of Science ®Google Scholar
• Justice, A. C., Rabeneck, L., Hays, R. D., Wu, A. W., & Bozzette, S. A. (1999). Sensitivity, specificity, reliability, and clinical validity of provider-reported symptoms: A comparison with self-reported symptoms. Outcomes Committee of the AIDS Clinical Trials Group. Journal of Acquired Immune Deficiency Syndrome, 21(2), 126–133.
   PubMed Web of Science ®Google Scholar
• Kenedi, C. A., & Goforth, H. W. (2011). A systematic review of the psychiatric side-effects of efavirenz. AIDS and Behavior, 15(8), 1803–1818. doi:10.1007/s10461-011-9939-5
   PubMed Web of Science ®Google Scholar
• King, M. S., Brun, S. C., & Kempf, D. J. (2005). Relationship between adherence and the development of resistance in antiretroviral-naive, HIV-1-infected patients receiving lopinavir/ritonavir or nelfinavir. The Journal of Infectious Diseases, 191(12), 2046–2052. doi:10.1086/430387
   PubMed Web of Science ®Google Scholar
• Medicines Adherence: Involving Patients in Decisions About Prescribed Medicines and Supporting Adherence. (2009). London: National Collaborating Centre for Primary Care (UK), Royal College of General Practitioners (UK). Retrieved from http://www.nice.org.uk/nicemedia/live/11766/43042/43042.pdf
   Google Scholar
• Miller, L. G., Liu, H., Hays, R. D., Golin, C. E., Beck, C. K., Asch, S. M., … Wenger, N. S. (2002). How well do clinicians estimate patients’ adherence to combination antiretroviral therapy? Journal of General Internal Medicine, 17(1), 1–11. doi: 10.1046/j.1525-1497.2002.09004.x
   PubMed Web of Science ®Google Scholar
• Mills, A. M., Antinori, A., Clotet, B., Fourie, J., Herrera, G., Hicks, C., … Boven, K. (2013). Neurological and psychiatric tolerability of rilpivirine (TMC278) vs. efavirenz in treatment-naive, HIV-1-infected patients at 48 weeks. HIV Medicine, 14(7), 391–400. doi:10.1111/hiv.12012
   PubMed Web of Science ®Google Scholar
• Murri, R., Ammassari, A., Trotta, M. P., De Luca, A., Melzi, S., Minardi, C., … Wu, A. W. (2004). Patient-reported and physician-estimated adherence to HAART: Social and clinic center-related factors are associated with discordance. Journal of General Internal Medicine, 19(11), 1104–1110. doi:10.1111/j.1525-1497.2004.30248.x
   PubMed Web of Science ®Google Scholar
• Nachega, J. B., Mugavero, M. J., Zeier, M., Vitoria, M., & Gallant, J. E. (2011). Treatment simplification in HIV-infected adults as a strategy to prevent toxicity, improve adherence, quality of life and decrease healthcare costs. Patient Preference and Adherence, 5, 357–367. doi:10.2147/PPA.S22771
   PubMed Web of Science ®Google Scholar
• Nelson, M. R., Elion, R. A., Cohen, C. J., Mills, A., Hodder, S. L., Segal-Maurer, S., … Stevens, M. (2013). Rilpivirine versus efavirenz in HIV-1-infected subjects receiving emtricitabine/tenofovir DF: Pooled 96-week data from ECHO and THRIVE Studies. HIV Clinical Trials, 14(3), 81–91. doi:10.1310/hct1403-81
   PubMed Web of Science ®Google Scholar
• Nelson, M. R., Girard, P. M., Demasi, R., Chen, L., Smets, E., Sekar, V., & Lavreys, L. (2010). Suboptimal adherence to darunavir/ritonavir has minimal effect on efficacy compared with lopinavir/ritonavir in treatment-naive, HIV-infected patients: 96 week ARTEMIS data. Journal of Antimicrobial Chemotherapy, 65(7), 1505–1509. doi:10.1093/jac/dkq150
   PubMed Web of Science ®Google Scholar
• Panel on Antiretroviral Guidelines for Adults and Adolescents. (2014). Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents (May 1, 2014). United States Department of Health and Human Services. Retrieved from http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf
   Google Scholar
• Paterson, D. L., Swindells, S., Mohr, J., Brester, M., Vergis, E. N., Squier, C., … Singh, N. (2000). Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Annals of Internal Medicine, 133(1), 21–30. doi: 10.7326/0003-4819-133-1-200007040-00004
   PubMed Web of Science ®Google Scholar
• Report on the Global AIDS Epidemic. (2008). Geneva: Joint United Nations Programme on HIV/AIDS (UNAIDS). Retrieved from http://www.unaids.org/en/media/unaids/contentassets/dataimport/pub/globalreport/2008/jc1510_2008globalreport_en.pdf
   Google Scholar
• Sustiva® (efavirenz) capsules and tablets. (2013). (US ed.). Princeton, NJ Bristol-Myers Squibb Company. Retrieved from http://packageinserts.bms.com/pi/pi_sustiva.pdf
   Google Scholar
• Thompson, M. A., Mugavero, M. J., Amico, K. R., Cargill, V. A., Chang, L. W., Gross, R., … Nachega, J. B. (2012). Guidelines for improving entry into and retention in care and antiretroviral adherence for persons with HIV: Evidence-based recommendations from an International Association of Physicians in AIDS Care panel. Annals of Internal Medicine, 156(11), 817–833. doi:10.7326/0003-4819-156-11-201206050-00419
   PubMed Web of Science ®Google Scholar
• Wagner, J. H., Justice, A. C., Chesney, M., Sinclair, G., Weissman, S., & Rodriguez-Barradas, M. (2001). Patient- and provider-reported adherence: Toward a clinically useful approach to measuring antiretroviral adherence. Journal of Clinical Epidemiology, 54(Suppl. 1), S91–S98. doi: 10.1016/S0895-4356(01)00450-4
   Google Scholar
• Walsh, J. C., Mandalia, S., & Gazzard, B. G. (2002). Responses to a 1 month self-report on adherence to antiretroviral therapy are consistent with electronic data and virological treatment outcome. AIDS, 16(2), 269–277. doi: 10.1097/00002030-200201250-00017
   PubMed Web of Science ®Google Scholar
• Ware, J. Jr., Kosinski, M., & Keller, S. D. (1996). A 12-item short-form health survey: Construction of scales and preliminary tests of reliability and validity. Medical Care, 34(3), 220–233. doi: 10.1097/00005650-199603000-00003
   PubMed Web of Science ®Google Scholar
• Woodcock, A., & Bradley, C. (2001). Validation of the HIV treatment satisfaction questionnaire (HIVTSQ). Quality of Life Research, 10(6), 517–531. doi: 10.1023/A:1013050904635
   PubMed Web of Science ®Google Scholar
• Woodcock, A., & Bradley, C. (2006). Validation of the revised 10-item HIV treatment satisfaction questionnaire status version and new change version. Value in Health, 9(5), 320–333. doi:10.1111/j.1524-4733.2006.00121.x
   PubMed Web of Science ®Google Scholar